PureTech Health plc
http://www.puretechhealth.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From PureTech Health plc
Coronavirus Notebook: UK Begins COVID-19 Vaccine Rollout, Government May Enlist Military Backup
EU passes legislation allowing VAT exemption for coronavirus vaccines to make them more affordable, as two treatments for severe disease and “Long COVID” respectively enter Phase II trials.
Tech Transfer Roundup: NCI Licenses Leukemia, Brain Cancer Candidates To Vor, Connectyx
NIH’s National Cancer Institute licensed two experimental cancer therapies in the past month to biopharma firms, leading a heavy slate of cancer-focused tech transfer deal-making.
Silver Linings: COVID-19 Creates Investment Bubble, Golden R&D Era
A choice asset in the middle of a pandemic, pharma companies could see the investment bubble burst once normalcy is on the horizon. But interest will continue in innovators, rather than big pharma specifically, predicts an expert panel featuring Biogen's chairman, a former Sanofi CEO and an ex-NIH director.
Finance Watch: As Exit Values Rise, More Money Flows Into VC Investments
Private Company Edition: The average exit from biopharma investments rose from $356.8m in 2019 to $520.6m in 2020, explaining the staggering $12bn invested in the industry during the first half of this year versus $17bn for all of last year. In recent VC deals, VelosBio’s $137m series B was the largest.
Company Information
- Industry
- Biotechnology
- Medical Devices
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
- Site Specific
-
Drug Delivery
-
Biotechnology
- Antisense, Oligonucleotides
- Large Molecule
- Other Names / Subsidiaries
-
- Vedanta Biosciences, Inc.
- Alivio Therapeutics, Inc.
- resTORbio, Inc.
- Tal Medical
- Vor Biopharma